• If you are wondering whether Guardian Pharmacy Services at US$37.66 is priced for opportunity or already reflecting high expectations, the valuation picture is the key place to focus next.
• The stock has posted returns of 0.2% over the last 7 days, 12.4% over the last 30 days, 27.5% year to date and 79.2% over the past year. This naturally raises questions about how much of the story is already in the price.
• Recent news coverage has centered on Guardian Pharmacy Services as a healthcare name that has been drawing investor attention, with headlines highlighting its share price performance and position in the sector. This context helps frame whether recent enthusiasm lines up with a reasonable assessment of what the business might be worth.
• Despite this performance, the Simply Wall St valuation model currently gives Guardian Pharmacy Services a value score of 0 out of 6. The next sections will compare different valuation approaches and, by the end, point you to a broader way to think about the company’s value beyond any single metric.

Guardian Pharmacy Services scores just 0/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Guardian Pharmacy Services Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes projections of a company’s future cash flows and discounts them back to today’s value, aiming to estimate what the business might be worth based on those cash flows alone.

For Guardian Pharmacy Services, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is reported at $80.62 million. Analysts provide explicit $ free cash flow estimates out to 2027, with Simply Wall St extrapolating the following decade long path. This reaches a projected $105.25 million in 2035, all expressed in today’s terms using discounting.

Aggregating these discounted cash flows gives an estimated intrinsic value of about $34.43 per share. When compared with the current share price of $37.66, the DCF output points to the stock trading roughly 9.4% above this estimate. This places it in a zone where the model suggests the pricing is slightly richer than the calculated fair value, but not by a wide margin.

Result: ABOUT RIGHT

Guardian Pharmacy Services is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Approach 2: Guardian Pharmacy Services Price vs Earnings

For a profitable company, the P/E ratio is a useful yardstick because it links what you pay for each share to the earnings that support that price. Higher growth expectations or lower perceived risk typically justify a higher P/E, while slower growth or higher risk usually points to a lower, more conservative P/E as being “normal” for a stock.

Guardian Pharmacy Services currently trades on a P/E of 48.45x. That sits above the Healthcare industry average of about 21.79x and also above the peer group average of 40.35x, which suggests the market is assigning a relatively premium earnings multiple compared with both the sector and closer comparators.

Simply Wall St’s Fair Ratio is a proprietary estimate of what P/E might be reasonable for Guardian Pharmacy Services, given its earnings growth profile, industry, profit margins, market cap and risk characteristics. Because it blends all of these factors, the Fair Ratio can give a more tailored reference point than a simple comparison with industry or peer averages. For Guardian Pharmacy Services, the Fair Ratio stands at 22.88x, which is materially below the current P/E of 48.45x, indicating the shares are priced above this modelled reference level.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Guardian Pharmacy Services Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives on Simply Wall St let you set your own story for Guardian Pharmacy Services, link that story to a forecast for revenue, earnings and margins, and see the fair value that drops out. All of this is available within an easy tool on the Community page that updates as new news or earnings arrive. One investor might build a Narrative around the analyst consensus fair value of US$34 per share, while another uses the same data on revenue growth, margins and future P/E to justify a higher or lower fair value, then compare each view with the current price to decide whether the stock looks attractive, fully priced or expensive according to their own assumptions.

Do you think there's more to the story for Guardian Pharmacy Services? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.